Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of SAR441344, a CD40L-antagonist monoclonal antibody, in relapsing multiple sclerosis
2020-004785-19Phase 2Active
- Sponsor
- Sanofi
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing SAR441344 with Placebo (2 arms). Primary endpoint: Number of new gadolinium-enhancing T1 hyperintense brain lesions. Started Jan 2021; status: active.
02
Drugs
frexalimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2020-004785-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004785-19.